Kala Pharmaceuticals Co-founder Publishes Data on Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes Simplex Virus-2 Infection

Published: Jul 12, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, announced a publication by company co-founder Justin Hanes, PhD in Science Translational Medicine showing promising effects of its Mucosal-Penetrating Products (MPPs) in preventing Herpes Simplex Virus-2 (HSV-2) infection.

Back to news